Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
147 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2016', provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury) - The report reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics and enlists all their major and minor projects - The report assesses Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Acute Renal Failure (ARF) (Acute Kidney Injury) Overview 10 Therapeutics Development 11 Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview 11 Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis 12 Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Development by Companies 13 Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Investigation by Universities/Institutes 15 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Development by Companies 18 Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Investigation by Universities/Institutes 20 Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development 21 A1M Pharma AB 21 Adrenomed AG 22 Am-Pharma B.V. 23 Angion Biomedica Corp. 24 Atox Bio Inc. 25 Cellmid Limited 26 Complexa, Inc. 27 DiaMedica Inc. 28 Digna Biotech, S.L. 29 DURECT Corporation 30 F. Hoffmann-La Roche Ltd. 31 G1 Therapeutics, Inc. 32 Ischemix, Inc. 33 Kringle Pharma, Inc. 34 NephroGenex, Inc. 35 NeuroVive Pharmaceutical AB 36 Noorik Biopharmaceuticals AG 37 Noxxon Pharma AG 38 Nyken B.V. 39 Orion Oyj 40 ProMetic Life Sciences Inc. 41 Quark Pharmaceuticals, Inc. 42 SBI Pharmaceuticals Co., Ltd. 43 Spherium Biomed S.L. 44 STATegics, Inc. 45 Thrasos Therapeutics Inc. 46 Torrent Pharmaceuticals Limited 47 Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment 48 Assessment by Monotherapy Products 48 Assessment by Combination Products 49 Assessment by Target 50 Assessment by Mechanism of Action 52 Assessment by Route of Administration 54 Assessment by Molecule Type 56 Drug Profiles 58 (aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 A1M-001 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 AB-103 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 adrecizumab - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 BB-3 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 CAB-101 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Cardiotrophin-1 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Cell Therapy to Activate Wnt7b for Kidney Injury - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 CMX-2043 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 CXA-10 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 cyclosporine - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 DM-199 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 DUR-928 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 HYPER-IL-6 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 KP-100IT - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 levosimendan - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 MG-53 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 MTP-131 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 N-003 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 NOXD-21 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 NYK-1341 - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 PBI-4419 - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 Pyridoxamine Dihydrochloride - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 QPI-1002 - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 R-190 - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 Recombinant Human Alkaline Phosphatase Replacement for Ulcerative Colitis, Acute Renal Failure, Sepsis and Hypophosphatasia - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 Recombinant Protein for Sepsis, Inflammatory Bowel Disease, Acute Kidney Injury, Acute Radiation Syndrome and Ischemic Organ Injury - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 RLS-003 - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 RO-6839328 - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile 106 Product Description 106 Mechanism of Action 106 R&D Progress 106 Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile 107 Product Description 107 Mechanism of Action 107 R&D Progress 107 SP-15016 - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 STSE-15 - Drug Profile 109 Product Description 109 Mechanism of Action 109 R&D Progress 109 THR-184 - Drug Profile 111 Product Description 111 Mechanism of Action 111 R&D Progress 111 TRC-160334 - Drug Profile 113 Product Description 113 Mechanism of Action 113 R&D Progress 113 Acute Renal Failure (ARF) (Acute Kidney Injury) - Recent Pipeline Updates 114 Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects 138 Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products 139 Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones 140 Featured News & Press Releases 140 Jan 06, 2016: DURECT Announces Positive Phase 1 Data for DUR-928 140 Dec 14, 2015: NephroGenex Announces FDA Clearance Of IND Application For Clinical Study Of Intravenous Pyridorin In The Treatment Of Acute Kidney Injury 140 Dec 09, 2015: Ischemix Announces First International Patent Coverage of Novel Analogs of its Lead Cytoprotective Compound 141 Nov 19, 2015: NeuroVive reports favourable safety evaluation in Phase II acute kidney injury study 141 Nov 10, 2015: Thrasos Strengthens Composition of Matter Coverage on THR-184 with Japanese Patent Decision 142 Nov 04, 2015: DiaMedica Provides Corporate Update 142 Nov 04, 2015: NephroGenex Announces Successful Results from Toxicity Study of Intravenous Pyridorin 144 Nov 02, 2015: Angion Biomedica to Present Clinical and Preclinical Data at the Upcoming American Society of Nephrology Conference in San Diego 144 Oct 30, 2015: Licensee's drug to commence Phase 2 and Phase 3 trials 145 Jul 07, 2015: Thrasos Completes Enrollment of Phase 2 THR-184 Clinical Study for Acute Kidney Injury 145 Appendix 146 Methodology 146 Coverage 146 Secondary Research 146 Primary Research 146 Expert Panel Validation 146 Contact Us 146 Disclaimer 147
List of Tables Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2016 11 Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Number of Products under Development by Companies, H1 2016 (Contd..1) 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Development by Companies, H1 2016 (Contd..1) 19 Products under Investigation by Universities/Institutes, H1 2016 20 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB, H1 2016 21 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Adrenomed AG, H1 2016 22 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma B.V., H1 2016 23 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp., H1 2016 24 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Atox Bio Inc., H1 2016 25 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cellmid Limited, H1 2016 26 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Complexa, Inc., H1 2016 27 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DiaMedica Inc., H1 2016 28 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Digna Biotech, S.L., H1 2016 29 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DURECT Corporation, H1 2016 30 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 31 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by G1 Therapeutics, Inc., H1 2016 32 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Ischemix, Inc., H1 2016 33 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma, Inc., H1 2016 34 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NephroGenex, Inc., H1 2016 35 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NeuroVive Pharmaceutical AB, H1 2016 36 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Noorik Biopharmaceuticals AG, H1 2016 37 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Noxxon Pharma AG, H1 2016 38 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Nyken B.V., H1 2016 39 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Orion Oyj, H1 2016 40 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by ProMetic Life Sciences Inc., H1 2016 41 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Quark Pharmaceuticals, Inc., H1 2016 42 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by SBI Pharmaceuticals Co., Ltd., H1 2016 43 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Spherium Biomed S.L., H1 2016 44 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics, Inc., H1 2016 45 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Thrasos Therapeutics Inc., H1 2016 46 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Torrent Pharmaceuticals Limited, H1 2016 47 Assessment by Monotherapy Products, H1 2016 48 Assessment by Combination Products, H1 2016 49 Number of Products by Stage and Target, H1 2016 51 Number of Products by Stage and Mechanism of Action, H1 2016 53 Number of Products by Stage and Route of Administration, H1 2016 55 Number of Products by Stage and Molecule Type, H1 2016 57 Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics - Recent Pipeline Updates, H1 2016 114 Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H1 2016 138 Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H1 2016 139
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
